Abstract

Angiogenesis is vital in the process of primary tumor growth, proliferation and metastasis. In many cancers, including non-small cell lung cancer (NSCLC), inhibition of tumor angiogenesis has been identified as an important therapy. The most common drugs include bevacizumab, ramucirumab, tyrosine kinase inhibitor such as sorafenib tosylate, and nintedanib. We will summarize the research about some inhibition of tumor angiogenesis. Key words: Angiogenesis inhibitors/TU; Carcinoma, non-small-cell lung/DT; Review

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.